Tirdzniecība PLx Pharma Inc. - PLXP CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.05 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 0.58 |
| Atvērt* | 0.54 |
| Izmaiņas par 1 gadu* | 42.11% |
| Dienas Diapazons* | 0.38 - 0.54 |
| 52 ned Diapazons | 0.12-4.43 |
| Vidējais apjoms (10 dienas) | 243.14K |
| Vidējais apjoms (3 mēneši) | 7.89M |
| Tirgus Kapitalizācija | 4.66M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 29.14M |
| Ieņēmumi | 4.54M |
| EPS | -0.99 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 3.85 |
| Nākamās Peļņas Datums | Mar 27, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Nov 11, 2022 | 0.38 | -0.16 | -29.63% | 0.54 | 0.54 | 0.38 |
| Nov 10, 2022 | 0.58 | -0.02 | -3.33% | 0.60 | 0.60 | 0.57 |
| Nov 9, 2022 | 0.57 | 0.00 | 0.00% | 0.57 | 0.59 | 0.57 |
| Nov 8, 2022 | 0.58 | -0.02 | -3.33% | 0.60 | 0.60 | 0.57 |
| Nov 7, 2022 | 0.63 | 0.07 | 12.50% | 0.56 | 0.63 | 0.56 |
| Nov 4, 2022 | 0.60 | -0.01 | -1.64% | 0.61 | 0.67 | 0.56 |
| Nov 3, 2022 | 0.61 | 0.03 | 5.17% | 0.58 | 0.62 | 0.58 |
| Nov 2, 2022 | 0.58 | 0.00 | 0.00% | 0.58 | 0.61 | 0.57 |
| Nov 1, 2022 | 0.58 | 0.00 | 0.00% | 0.58 | 0.59 | 0.57 |
| Oct 31, 2022 | 0.59 | 0.00 | 0.00% | 0.59 | 0.60 | 0.57 |
| Oct 28, 2022 | 0.58 | 0.02 | 3.57% | 0.56 | 0.60 | 0.56 |
| Oct 27, 2022 | 0.56 | 0.00 | 0.00% | 0.56 | 0.57 | 0.56 |
| Oct 26, 2022 | 0.57 | 0.03 | 5.56% | 0.54 | 0.57 | 0.54 |
| Oct 25, 2022 | 0.53 | -0.02 | -3.64% | 0.55 | 0.56 | 0.52 |
| Oct 24, 2022 | 0.58 | 0.00 | 0.00% | 0.58 | 0.60 | 0.58 |
| Oct 21, 2022 | 0.58 | 0.00 | 0.00% | 0.58 | 0.60 | 0.58 |
| Oct 20, 2022 | 0.58 | 0.00 | 0.00% | 0.58 | 0.60 | 0.58 |
| Oct 19, 2022 | 0.58 | 0.01 | 1.75% | 0.57 | 0.61 | 0.57 |
| Oct 18, 2022 | 0.57 | -0.02 | -3.39% | 0.59 | 0.59 | 0.55 |
| Oct 17, 2022 | 0.56 | 0.03 | 5.66% | 0.53 | 0.59 | 0.53 |
PLx Pharma Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 8.208 | 0.03043 | 0.56546 | 0.75311 | 0.77866 |
| Ienākumi | 8.208 | 0.03043 | 0.56546 | 0.75311 | 0.77866 |
| Kopējie Darbības Izdevumi | 48.998 | 13.4895 | 14.7678 | 11.7143 | 16.6265 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 40.011 | 9.15057 | 10.0266 | 7.7916 | 10.175 |
| Pētniecība un Attīstība | 4.182 | 4.33897 | 4.74113 | 3.92267 | 4.15745 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 2.29405 | |||
| Darbības Izdevumi | -40.79 | -13.4591 | -14.2023 | -10.9612 | -15.8478 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -5.335 | -1.75154 | -6.3001 | 11.8576 | -0.41889 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -46.125 | -15.2107 | -20.5024 | 0.89648 | -16.2667 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -46.125 | -15.2107 | -20.5024 | 0.89648 | -15.3467 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -46.125 | -15.2107 | -20.5024 | 0.89648 | -15.3467 |
| Neto Ienākumi | -46.125 | -15.2107 | -20.5024 | 0.89648 | -15.3467 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -48.65 | -16.948 | -34.2532 | 0.89648 | -15.3467 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -48.65 | -16.948 | -34.2532 | 0.89648 | -15.3467 |
| Atšķaidītie Neto Ienākumi | -48.65 | -16.948 | -34.2532 | 0.89648 | -15.3467 |
| Atšķaidītie Ienākumi par Akcijām | 23.6505 | 9.71495 | 8.91619 | 8.73322 | 7.02048 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.05704 | -1.74452 | -3.84169 | 0.10265 | -2.18599 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -2.05704 | -1.74452 | -3.84169 | 0.10265 | -1.9736 |
| Total Adjustments to Net Income | -2.525 | -1.7373 | -13.7508 | ||
| Cost of Revenue, Total | 4.805 | ||||
| Bruto Peļņa | 3.403 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 2.083 | 1.5919 | 6.6161 | 0 | 0 |
| Ienākumi | 2.083 | 1.5919 | 6.6161 | 0 | 0 |
| Kopējie Darbības Izdevumi | 20.279 | 22.4437 | 16.4779 | 6.48048 | 3.59583 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 18.456 | 20.8637 | 11.0132 | 5.49775 | 2.63633 |
| Pētniecība un Attīstība | 0.654 | 0.68778 | 1.55199 | 0.98273 | 0.9595 |
| Darbības Izdevumi | -18.196 | -20.8518 | -9.86185 | -6.48048 | -3.59583 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 7.411 | 24.4142 | -11.7807 | -10.0239 | -7.94468 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -10.785 | 3.56237 | -21.6425 | -16.5044 | -11.5405 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -10.785 | 3.56237 | -21.6425 | -16.5044 | -11.5405 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -10.785 | 3.56237 | -21.6425 | -16.5044 | -11.5405 |
| Neto Ienākumi | -10.785 | 3.56237 | -21.6425 | -16.5044 | -11.5405 |
| Total Adjustments to Net Income | 0 | -0.00004 | 0 | -2.20269 | -0.32227 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -10.785 | 3.56233 | -21.6425 | -18.7071 | -11.8628 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -10.785 | 3.56233 | -21.6425 | -18.7071 | -11.8628 |
| Atšķaidītie Neto Ienākumi | -10.785 | 3.56233 | -21.6425 | -18.7071 | -11.8628 |
| Atšķaidītie Ienākumi par Akcijām | 27.5392 | 27.5742 | 26.9119 | 23.6382 | 16.3616 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.39162 | 0.12919 | -0.8042 | -0.79139 | -0.72504 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.39162 | 0.12919 | -0.8042 | -0.79139 | -0.72504 |
| Cost of Revenue, Total | 1.169 | 0.89226 | 3.91274 | ||
| Bruto Peļņa | 0.914 | 0.69964 | 2.70336 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 73.476 | 22.9855 | 14.2833 | 14.8654 | 25.69 |
| Nauda un Īstermiņa Ieguldījumi | 69.392 | 22.4487 | 14.0013 | 14.2503 | 24.4044 |
| Nauda un Ekvivalenti | 69.392 | 22.4487 | 14.0013 | 14.2503 | 24.4044 |
| Debitoru Parādu Kopsumma, Neto | 0.634 | 0 | 0.01868 | 0.01823 | 0.01938 |
| Accounts Receivable - Trade, Net | 0.634 | 0 | 0.01868 | 0.01823 | 0.01938 |
| Total Inventory | 2.458 | 0.14338 | 0 | 0.24637 | |
| Prepaid Expenses | 0.992 | 0.39347 | 0.26327 | 0.40937 | 0.30017 |
| Other Current Assets, Total | 0 | 0.18754 | 0.71967 | ||
| Total Assets | 76.642 | 26.6166 | 18.5028 | 18.3884 | 28.8486 |
| Property/Plant/Equipment, Total - Net | 1.088 | 1.55304 | 2.0848 | 1.39423 | 1.02988 |
| Goodwill, Net | 2.061 | 2.06102 | 2.06102 | 2.06102 | 2.06102 |
| Intangibles, Net | |||||
| Other Long Term Assets, Total | 0.017 | 0.01704 | 0.07367 | 0.06771 | 0.06771 |
| Total Current Liabilities | 11.879 | 3.54231 | 6.09343 | 4.73266 | 1.81569 |
| Payable/Accrued | 10.6 | 0.86257 | 0.92892 | 0.65305 | 0.85216 |
| Accrued Expenses | 1.278 | 2.02327 | 1.50639 | 1.1699 | 0.96354 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 24.962 | 16.1636 | 16.9331 | 11.9441 | 24.2322 |
| Total Long Term Debt | 0 | 0 | 0.62227 | 4.28039 | 6.94215 |
| Other Liabilities, Total | 13.083 | 12.6213 | 10.2174 | 2.93104 | 15.4743 |
| Total Equity | 51.68 | 10.453 | 1.56962 | 6.44429 | 4.61639 |
| Common Stock | 0.028 | 0.01391 | 0.00916 | 0.00874 | 0.00872 |
| Additional Paid-In Capital | 183.912 | 91.203 | 74.8371 | 72.8713 | 71.9399 |
| Retained Earnings (Accumulated Deficit) | -148.274 | -102.149 | -86.9382 | -66.4358 | -67.3323 |
| Total Liabilities & Shareholders’ Equity | 76.642 | 26.6166 | 18.5028 | 18.3884 | 28.8486 |
| Total Common Shares Outstanding | 27.5392 | 13.9116 | 9.15626 | 8.74395 | 8.72282 |
| Property/Plant/Equipment, Total - Gross | 1.553 | 2.00154 | 2.52769 | 1.68631 | 1.479 |
| Accumulated Depreciation, Total | -0.465 | -0.4485 | -0.44288 | -0.29208 | -0.44912 |
| Long Term Debt | 0 | 0.62227 | 4.28039 | 6.94215 | |
| Current Port. of LT Debt/Capital Leases | 0 | 0.62227 | 3.65812 | 2.90971 | |
| Preferred Stock - Non Redeemable, Net | 16.014 | 21.3849 | 13.6616 | ||
| Other Current Liabilities, Total | 0.001 | 0.03421 | |||
| Total Preferred Shares Outstanding | 0.01501 | 0.023 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 57.748 | 73.476 | 88.6142 | 82.013 | 84.8674 |
| Nauda un Īstermiņa Ieguldījumi | 52.499 | 69.392 | 82.5543 | 80.1695 | 84.4235 |
| Nauda un Ekvivalenti | 52.499 | 69.392 | 82.5543 | 80.1695 | 84.4235 |
| Total Inventory | 3.839 | 2.458 | 2.19035 | 1.26248 | 0.14338 |
| Prepaid Expenses | 0.712 | 0.992 | 0.61625 | 0.58101 | 0.30056 |
| Total Assets | 60.858 | 76.642 | 91.8361 | 85.3085 | 88.3209 |
| Property/Plant/Equipment, Total - Net | 1.032 | 1.088 | 1.14378 | 1.21751 | 1.37546 |
| Goodwill, Net | 2.061 | 2.061 | 2.06102 | 2.06102 | 2.06102 |
| Other Long Term Assets, Total | 0.017 | 0.017 | 0.01704 | 0.01704 | 0.01704 |
| Total Current Liabilities | 13.23 | 11.879 | 7.40538 | 3.06477 | 1.40919 |
| Payable/Accrued | 12.716 | 10.6 | 6.45217 | 2.38232 | 0.96261 |
| Accrued Expenses | 0.51113 | 1.278 | 0.95321 | 0.64824 | 0.41238 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 0.00287 | 0.001 | 0.03421 | 0.03421 | |
| Total Liabilities | 18.875 | 24.962 | 44.9288 | 29.1794 | 22.2751 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 5.645 | 13.083 | 37.5234 | 26.1146 | 20.8659 |
| Total Equity | 41.983 | 51.68 | 46.9073 | 56.1292 | 66.0459 |
| Preferred Stock - Non Redeemable, Net | 16.014 | 16.014 | 16.0136 | 16.0136 | 21.3849 |
| Common Stock | 0.028 | 0.028 | 0.02748 | 0.02615 | 0.02284 |
| Additional Paid-In Capital | 185 | 183.912 | 182.702 | 170.283 | 158.327 |
| Retained Earnings (Accumulated Deficit) | -159.059 | -148.274 | -151.836 | -130.194 | -113.689 |
| Total Liabilities & Shareholders’ Equity | 60.858 | 76.642 | 91.8361 | 85.3085 | 88.3209 |
| Total Common Shares Outstanding | 27.5392 | 27.5392 | 27.477 | 26.145 | 22.8363 |
| Total Preferred Shares Outstanding | 0.01501 | 0.01501 | 0.01501 | 0.01501 | 0.023 |
| Debitoru Parādu Kopsumma, Neto | 0.698 | 0.634 | 3.25331 | ||
| Accounts Receivable - Trade, Net | 0.698 | 0.634 | 3.25331 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -46.125 | -15.2107 | -20.5024 | 0.89648 | -15.3467 |
| Nauda no Darbības | -32.118 | -12.2436 | -12.659 | -9.49923 | -13.3066 |
| Nauda no Darbības | 0.116 | 0.12462 | 0.15825 | 0.20096 | 0.02984 |
| Deferred Taxes | 0 | -0.92 | |||
| Bezskaidras Naudas Preces | 8.38 | 3.04205 | 6.8139 | -10.8456 | 4.91663 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Samaksātie Procenti Naudā | 0.006 | 0.21286 | 0.6003 | 0.67115 | 0.19594 |
| Izmaiņas Apgrozāmajā Kapitālā | 5.511 | -0.19961 | 0.8712 | 0.24895 | -1.9863 |
| Nauda no Ieguldījumu Darbībām | 0.095 | -0.102 | -0.23029 | -0.65487 | 11.2389 |
| Kapitālie Izdevumi | 0 | -0.102 | -0.24174 | -0.65487 | -0.53757 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 0.095 | 0.01144 | 0 | 11.7764 | |
| Nauda no Darbībām ar Finansēšanu | 78.966 | 20.7929 | 12.6404 | 0 | 26.4127 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 79.591 | 24.5429 | 15.7654 | 0 | 23.8444 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -0.625 | -3.75 | -3.125 | 0 | 2.5683 |
| Neto Izmaiņas Naudā | 46.943 | 8.44735 | -0.24896 | -10.1541 | 24.345 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.785 | -46.125 | -49.6874 | -28.0449 | -11.5405 |
| Cash From Operating Activities | -16.893 | -32.118 | -18.7567 | -9.75913 | -4.28206 |
| Cash From Operating Activities | 0.03 | 0.116 | 0.08574 | 0.05554 | 0.02656 |
| Non-Cash Items | -6.32 | 8.38 | 31.7794 | 19.2826 | 8.61713 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0 | 0.006 | 0.00649 | 0.00649 | 0.60195 |
| Changes in Working Capital | 0.182 | 5.511 | -0.93438 | -1.05234 | -1.38523 |
| Cash From Investing Activities | 0.095 | 0.09454 | 0.04524 | 0 | |
| Capital Expenditures | 0 | 0 | 0 | ||
| Cash From Financing Activities | 0 | 78.966 | 78.7678 | 67.4347 | 66.2569 |
| Issuance (Retirement) of Stock, Net | 0 | 79.591 | 79.3928 | 68.0597 | 66.8819 |
| Issuance (Retirement) of Debt, Net | 0 | -0.625 | -0.625 | -0.625 | -0.625 |
| Net Change in Cash | -16.893 | 46.943 | 60.1057 | 57.7208 | 61.9748 |
| Other Investing Cash Flow Items, Total | 0.095 | 0.09454 | 0.04524 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Level One Partners LLC | Corporation | 9.5157 | 2772643 | 1452337 | 2021-12-31 | |
| White Rock Capital Management, L.P. | Hedge Fund | 7.4574 | 2172900 | 852594 | 2021-12-31 | |
| Park West Asset Management LLC | Hedge Fund | 5.0561 | 1473218 | 0 | 2022-12-31 | MED |
| Hardie Robert D | Individual Investor | 4.0223 | 1172000 | 297000 | 2021-12-31 | |
| Green Square Capital Advisors, LLC | Investment Advisor | 3.3874 | 987000 | 794000 | 2022-12-31 | LOW |
| Valentino (Michael J) | Individual Investor | 1.6978 | 494690 | 0 | 2022-09-19 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4013 | 408320 | 733 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1618 | 338522 | -777284 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8151 | 237491 | -13361 | 2022-12-31 | LOW |
| Ground Swell Capital, LLC | Investment Advisor | 0.751 | 218820 | 176311 | 2022-12-31 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.6607 | 192504 | 192504 | 2022-12-31 | HIGH |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.6513 | 189785 | -44319 | 2022-12-31 | LOW |
| University of Texas Investment Management Company | Endowment Fund | 0.4302 | 125346 | 0 | 2022-12-31 | LOW |
| HRT Financial LP | Investment Advisor | 0.2984 | 86942 | 86942 | 2022-12-31 | HIGH |
| UBS Financial Services, Inc. | Investment Advisor | 0.2873 | 83723 | 27752 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.2835 | 82604 | -179302 | 2022-12-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2716 | 79132 | 0 | 2022-12-31 | LOW |
| Virtu Americas LLC | Research Firm | 0.2449 | 71368 | 71368 | 2022-12-31 | HIGH |
| Ergoteles Capital | Hedge Fund | 0.2086 | 60771 | 60771 | 2022-12-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.187 | 54500 | 54500 | 2022-12-31 | HIGH |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
PLx Pharma Inc. Company profile
Par PLx Pharma Inc.
PLx Pharma Inc. ir farmācijas uzņēmums. Uzņēmums koncentrējas uz savu zāļu piegādes platformu PLxGuard. Tās galvenais produkts ir VAZALORE, kas pieejams divās devās 325 miligramu (mg) un 81 mg, ir aspirīna preparāts, par kuru klīniski pierādīts, ka tas nodrošina trombocītu inhibīciju pacientiem ar asinsvadu slimībām un cukura diabēta pacientiem, kuri var būt kandidāti aspirīna terapijai. Tās PLxGuard piegādes sistēma izmanto virsmaktīvus lipīdus, piemēram, fosfolipīdus un brīvās taukskābes, lai modificētu dažādu zāļu fizikāli ķīmiskās īpašības ar mērķtiecīgu izdalīšanos uz izvēlētām gremošanas trakta daļām. Uzņēmuma ražojumu klāstā ir arī citi iekšķīgi lietojami nesteroīdie pretiekaisuma līdzekļi (NPL), izmantojot PLxGuard zāļu piegādes platformu, tostarp PL1200 Ibuprofēns 200 mg un PL1200 Ibuprofēns 400 mg, kas paredzēti sāpju un iekaisuma ārstēšanai I klīniskās fāzes posmā.
| Industry: | Pharmaceuticals (NEC) |
9 Fishers Ln Ste E
SPARTA
NEW JERSEY 07871-2402
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com